Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03515980
Other study ID # CV013-026
Secondary ID 2017-004914-24
Status Completed
Phase Phase 1
First received
Last updated
Start date May 25, 2018
Est. completion date August 29, 2019

Study information

Verified date August 2020
Source Bristol-Myers Squibb
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an investigational study of experimental Medication BMS-986231 given to participants with weakened or damaged liver function.


Recruitment information / eligibility

Status Completed
Enrollment 76
Est. completion date August 29, 2019
Est. primary completion date August 29, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

- Body weight = 45 kg and = 120 kg and BMI = 18 kg/m2 and = 35 kg/m2

- Heart rate = 50 bpm and < 95 bpm

- Women of childbearing potential must have a negative urine or serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of study treatment

Exclusion Criteria:

- Clinically relevant abnormal medical history, abnormal findings on physical examination, vital signs, ECG, or laboratory tests at Screening that the investigator judges as likely to interfere with the objectives of the trial or the safety of the volunteer

- History of chronic headaches (defined as occurring 15 days or more a month, over the previous 3 months), headaches related to caffeine withdrawal (ie, coffee, soda, tea, energy drinks, etc.), or moderately severe to severe headaches

- History of migraine or cluster headaches

Other protocol defined inclusion/exclusion criteria could apply

Study Design


Intervention

Drug:
BMS-986231
Intravenous (IV) administration

Locations

Country Name City State
Hungary Semmelweis Egyetem Altalanos Orvostudomanyi Kar Budapest
Hungary Clinical Research Unit Hungary Miskolc
Poland BioVirtus Centrum Medyczne Jozefow
Poland KO-MED Centra Kliniczne Lublin Lublin

Sponsors (1)

Lead Sponsor Collaborator
Bristol-Myers Squibb

Countries where clinical trial is conducted

Hungary,  Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area under the concentration-time curve from time 0 extrapolated to infinity [AUC(INF)] derived from plasma concentration Up to 2 days
Primary AUC from time 0 up to time T, where T is the last time point with concentrations above the lower limit of quantitation [AUC(0-T)] derived from plasma concentration Up to 2 days
Primary Maximum plasma concentration (Cmax) Up to 2 days
Secondary Incidence of adverse events (AE) Up to 33 days
Secondary Incidence of serious adverse events (SAE) Up to 33 days
Secondary Incidence of Laboratory Test Result Abnormalities Up to 11 days
Secondary Clearance (CL) derived from plasma concentration Up to 2 days
Secondary Terminal elimination half-life (t1/2) derived from plasma concentration Up to 2 days
Secondary Time of maximum observed plasma concentration (Tmax) Up to 2 days
Secondary Terminal elimination phase rate constant (?z) derived from plasma concentration Up to 2 days
Secondary Volume of distribution during terminal phase (Vz) derived from plasma concentration Up to 2 days
Secondary Metabolite ratio determined using AUC(INF) for metabolite/AUC(INF) for BMS-986231 [MRAUC(INF)] derived from plasma concentration Up to 2 days
See also
  Status Clinical Trial Phase
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Completed NCT05563701 - Evaluation of the LVivo Image Quality Scoring (IQS)
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT04037436 - Functional Exercise and Nutrition Education Program for Older Adults N/A
Recruiting NCT04703842 - Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction Phase 1/Phase 2
Terminated NCT05594940 - Heart Failure Monitoring With a Portable Ultrasound Device With Artificial Intelligence Assisted Tools: A Multi-Phase Observational Feasibility Study
Recruiting NCT04982081 - Treating Congestive HF With hiPSC-CMs Through Endocardial Injection Phase 1
Completed NCT04394754 - Evaluating Efficacy of Digital Health Technology in the Treatment of Congestive Heart Failure N/A
Active, not recruiting NCT01385176 - Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF) N/A
Not yet recruiting NCT05516290 - Evaluating Clinical Trial Experiences of Individuals With Congestive Heart Failure
Terminated NCT02788656 - Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan) Phase 4
Completed NCT02885636 - Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial Phase 3
Terminated NCT02205411 - Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation N/A
Completed NCT02252757 - Assess Measurements of Wireless Cardiac Output Device N/A
Completed NCT01362855 - Advance Care Planning Evaluation in Hospitalized Elderly Patients
Withdrawn NCT00346177 - Stem Cell Study for Patients With Heart Failure Phase 2
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Active, not recruiting NCT01058837 - SCD-HeFT 10 Year Follow-up N/A
Completed NCT00957541 - Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) Device Phase 2